Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Bausch + Lomb (NYSE/TSX: BLCO) has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) using an excimer laser. The acquisition strengthens BLCO's glaucoma portfolio by introducing a differentiated treatment approach that can be performed alongside cataract surgery.
The ELIOS system offers a tissue-friendly, non-thermal laser-based procedure for glaucoma, which is expected to see a 47% prevalence increase from 2020 to 2040. The technology is currently CE marked and available in the European Union, with FDA approval pending. Over 19% of cataract surgery patients also have glaucoma or ocular hypertension, presenting an opportunity for concurrent treatment.
Bausch + Lomb (NYSE/TSX: BLCO) ha acquisito Elios Vision, Inc., sviluppatore della procedura ELIOS™, la prima chirurgia glaucoma clinicamente valida e minimamente invasiva (MIGS) che utilizza un laser a eccimeri. L'acquisizione rafforza il portafoglio di glaucoma di BLCO introducendo un approccio terapeutico differenziato che può essere eseguito contemporaneamente alla chirurgia della cataratta.
Il sistema ELIOS offre una procedura laser non termica e rispettosa dei tessuti per il glaucoma, che si prevede avrà un incremento della prevalenza del 47% dal 2020 al 2040. La tecnologia è attualmente marchiata CE ed è disponibile nell'Unione Europea, con approvazione FDA in attesa. Oltre il 19% dei pazienti sottoposti a chirurgia della cataratta presenta anche glaucoma o ipertensione oculare, offrendo un'opportunità per un trattamento simultaneo.
Bausch + Lomb (NYSE/TSX: BLCO) ha adquirido Elios Vision, Inc., desarrollador del procedimiento ELIOS™, la primera cirugía de glaucoma mínimamente invasiva clínicamente validada (MIGS) que utiliza un láser excimer. La adquisición refuerza el portafolio de glaucoma de BLCO al introducir un enfoque de tratamiento diferenciado que se puede realizar junto con la cirugía de cataratas.
El sistema ELIOS ofrece un procedimiento basado en láser no térmico y amigable con los tejidos para el glaucoma, que se espera que experimente un incremento del 47% en la prevalencia de 2020 a 2040. La tecnología tiene actualmente marcado CE y está disponible en la Unión Europea, con aprobación de la FDA pendiente. Más del 19% de los pacientes que se someten a cirugía de cataratas también padecen glaucoma o hipertensión ocular, presentando una oportunidad para un tratamiento concurrente.
바우슈 + 롬 (NYSE/TSX: BLCO)이 엘리오스 비전(Elios Vision, Inc.)을 인수하였습니다. 엘리오스 비전은ELIOS™ 절차의 개발자로, 임상적으로 검증된 최초의 미세침습 녹내장 수술(MIGS)입니다. 이 인수는 백내장 수술과 함께 시행할 수 있는 차별화된 치료 접근법을 도입함으로써 BLCO의 녹내장 포트폴리오를 강화합니다.
ELIOS 시스템은 조직 친화적이고 비열적 레이저 기반의 녹내장 절차를 제공하며, 2020년에서 2040년까지47%의 유병률 증가가 예상됩니다. 이 기술은 현재 CE 인증을 받았으며 유럽 연합에서 사용 가능하며, FDA 승인은 대기 중입니다. 백내장 수술을 받은 환자의 19% 이상이 녹내장이나 안압 상승을 겪고 있어 동시 치료의 기회를 제공합니다.
Bausch + Lomb (NYSE/TSX: BLCO) a acquis Elios Vision, Inc., développeur de la procédure ELIOS™, la première chirurgie du glaucome validée cliniquement et minimement invasive (MIGS) utilisant un laser excimer. L'acquisition renforce le portefeuille de glaucome de BLCO en introduisant une approche de traitement différenciée pouvant être réalisée en parallèle avec la chirurgie de la cataracte.
Le système ELIOS propose une procédure laser restituante et non thermique pour le glaucome, dont on s'attend à ce qu'elle connaisse une augmentation de prévalence de 47 % entre 2020 et 2040. La technologie est actuellement marquée CE et disponible dans l'Union européenne, l'approbation de la FDA étant en attente. Plus de 19 % des patients subissant une chirurgie de la cataracte souffrent également de glaucome ou d'hypertension oculaire, offrant ainsi une opportunité de traitement simultané.
Bausch + Lomb (NYSE/TSX: BLCO) hat Elios Vision, Inc. übernommen, den Entwickler des ELIOS™ Verfahrens, der ersten klinisch validierten minimally invasiven Glaukomoperation (MIGS) mit einem Excimerlaser. Die Übernahme stärkt das Glaukom-Portfolio von BLCO durch die Einführung eines differenzierten Behandlungsansatzes, der gleichzeitig mit der Kataraktoperation durchgeführt werden kann.
Das ELIOS-System bietet ein gewebefreundliches, nicht-thermisches laserbasiertes Verfahren für Glaukom, von dem ein 47% Anstieg der Prävalenz von 2020 bis 2040 erwartet wird. Die Technologie ist derzeit CE-zertifiziert und in der Europäischen Union verfügbar, die FDA-Zulassung steht noch aus. Über 19% der Patienten, die sich einer Kataraktoperation unterziehen, haben ebenfalls Glaukom oder okuläre Hypertension, was die Möglichkeit für eine gleichzeitige Behandlung eröffnet.
- Acquisition expands BLCO's glaucoma treatment portfolio
- ELIOS system already CE marked and marketed in EU
- Technology addresses growing market with 47% expected prevalence increase by 2040
- Synergistic with cataract surgery, targeting 19% of cataract patients with glaucoma
- Provides implant-free MIGS treatment option
- FDA approval still pending for US market entry
- Additional investment required for US regulatory process
Insights
The acquisition of Elios Vision marks a significant strategic expansion in Bausch + Lomb's glaucoma treatment portfolio. The ELIOS™ procedure represents a breakthrough in MIGS technology, offering a unique implant-free laser approach that can be performed alongside cataract surgery. With glaucoma prevalence projected to surge by
The synergistic potential is particularly compelling given that
This acquisition strategically positions BLCO to capture a larger share of the growing glaucoma treatment market. The deal enhances the company's competitive edge by adding a unique, implant-free MIGS technology to its portfolio. The immediate revenue potential in the EU market, coupled with future opportunities in the U.S. pending FDA approval, presents significant growth prospects. The ability to combine ELIOS with cataract procedures creates operational efficiencies and potential cost benefits for healthcare providers, which could drive adoption rates. While financial terms weren't disclosed, the acquisition's strategic fit and market expansion potential suggest positive implications for BLCO's long-term revenue growth and market position.
“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by
Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time.2 It can also often be performed in conjunction with cataract surgery, the most routinely performed surgery in the world.3 More than
“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma,” said Professor Ike K. Ahmed, MD, University of
“Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma,” said Elliot Friedman, former Elios Vision chairman and CEO. “The goal is to make combining cataract and glaucoma treatment the new standard of care, and that’s even more attainable given Bausch + Lomb’s presence in nearly 100 countries.”
The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Elios Vision is in the process of pursuing
Click here for a video demonstration of how ELIOS works.
Leerink Partners served as exclusive financial advisor to Elios Vision and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in
About Elios Vision, Inc.
Elios Vision Inc. is a privately held company, working to preserve sight by developing a safe and effective breakthrough solution for the millions of patients who have glaucoma.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the
References: |
1 Allison K, Patel D, Alabi O. Cureus. 2020 Nov 24. |
2 Gao X, Lv A, et al. BMJ Open. 2022 Jul 4;12(7):e062441. doi: 10.1136/bmjopen-2022-062441. PMID: 35788072; PMCID: PMC9255398. |
3 McGhee, CNJ, Zhang, J, Patel, DV. J Royal Society NZ, 2020 Jan. |
4 Tseng, VL, Yu, F, et al. JAMA. 2012 Aug. 1. |
© 2024 Bausch + Lomb.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211687982/en/
Media Contact:
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381
Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735
Source: Bausch + Lomb Corporation
FAQ
What is the strategic importance of BLCO's Elios Vision acquisition?
When will BLCO's ELIOS system be available in the United States?
What is the market potential for BLCO's ELIOS system?
Where is BLCO's ELIOS system currently available?
How does BLCO's ELIOS procedure differ from traditional glaucoma treatments?
